News and Events

Keep up-to-date on recent events, webinars and releases from ArcherDX.



Mar
5
2019

ArcherDX Announces Expansion of Executive Leadership Team as Company Continues to Experience Rapid Growth

ArcherDX Announces Expansion of Executive Leadership Team as Company Continues to Experience Rapid Growth


Feb
12
2019

Press release: ArcherDX Announces Broad-Based Strategic Collaboration with Genosity

ArcherDX, Inc. today announced that it has entered into a broad strategic collaboration with Genosity Inc., a biotechnology company that provides expertise, software and technical solutions to unlock the power of precision medicine by advancing genomics and facilitating collaborative research.


Jan
30
2019

Press release: ArcherDX Acquires Baby Genes, a Genetics-Based Personalized Medicine Company

ArcherDX is pleased to announce the acquisition of Baby Genes, Inc, a privately held CLIA-certified, CAP-accredited laboratory focused on empowering individuals to take charge of their health through genetic insights.


Jan
8
2019

Press release: ArcherDX’s Companion Diagnostic Assay for both Liquid Biopsy and Tissue Specimens Granted Breakthrough Device Designation by U.S. Food and Drug Administration

ArcherDX announced that the U.S. Food and Drug Administration (FDA) granted a Breakthrough Device designation (formerly Expedited Access Pathway program) for ArcherDx’s companion diagnostic assay application.


Oct
3
2018

Press release: Merck KGaA, Darmstadt, Germany Selects ArcherDX for Strategic Global Companion Diagnostic Assay Development Collaboration

ArcherDX and Merck KGaA, Darmstadt, Germany have entered into an agreement to develop and commercialize a next generation sequencing (NGS)-based companion diagnostic (CDx) assay.


Apr
12
2018

Press release: Washington University, ArcherDX partner for MRD in pediatric AML sequencing study

Washington University in St. Louis and ArcherDX will partner on a study to characterize and assess minimum residual disease (MRD) across 870 pediatric patients with acute myeloid leukemia (AML) using next-generation sequencing (NGS).


Mar
30
2018

Archer announces the 2018 Research Challenge Grant Winners

Archer awards 5 recipients up to 96 free reactions (12 kits with 8 reactions each) of an Archer Assay in the fields of mutation tracking, liquid biopsy and immune repertoire.


Mar
26
2018

Press release: ArcherDX and Ambry Genetics to provide immune repertoire and CAR-T- related sequencing services

ArcherDX and Ambry Genetics® announced today a partnership wherein Ambry will provide biopharma sequencing services employing ArcherDX’s next-generation sequencing (NGS) assays.


Mar
20
2018

Press release: ArcherDX Closes $35 Million Series A Financing

ArcherDX, Inc. announces that it has closed a $35 million Series A Preferred financing.


Feb
5
2018

2018 Research Challenge Grant

ArcherDX will award 96 reactions (12 kits) each to 3 recipients in the categories of mutation tracking, liquid biopsy and immune repertoire


Dec
19
2017

2017 Publications Spotlight

2017 Publications Spotlight


Nov
14
2017

Press release: ArcherDX receives EN ISO 13485 certification for medical device quality management

ArcherDX announces ISO 13485:2003 & EN ISO 13485:2012 certification indicating that the company’s quality management system maintains standards specific to medical devices, including in vitro diagnostic (IVD) assays


Nov
10
2017

Press release: ArcherDX, Celgene ink CDx development agreement

ArcherDX, Celgene ink worldwide companion diagnostic agreement relating to investigational drug CC-122


Oct
5
2017

Webinar - Archer VariantPlex myeloid assays

In this webinar we discuss how updates to the assay and software provide better coverage over challenging regions and enable lower limits of detection, high-resolution CNV detection and lightning-fast analysis that leverage and maximize the unique power of the patented Anchored Multiplex PCR (AMP™) target enrichment chemistry used in Archer NGS assays.


Apr
24
2017

Archer sponsors Breast Cancer research platform

ArcherDX is partnering with Susan G. Komen Colorado and the University of Colorado Cancer Center to create a local event to connect community physicians, patients, and advocates with academic researchers and industry leaders. Our vision is to provide an educational forum to raise awareness about advances in breast cancer research, treatment, and testing.


Apr
18
2017

Archer at 106th Annual Meeting of Japanese Society of Pathology in Tokyo

We'll be co-attending with Illumina at the inaugural Japanese Society of Pathology in Tokyo. We'll be presenting five posters at this event and giving away corresponding poster flyers with the lead scientist contact info for later review. This gathering will strive to establish a focus on diagnosis that is based on an integrated understanding of disease through the use of high-sensitivity, high-volume analytical technologies like next-generation sequencers and embrace the ideal of giving something back to medicine and society as the goal of pathology.


Mar
3
2017

Archer sponsors Snowshoe for the Cure

Archer partners with Susan G. Komen Colorado for the Snowshoe for the Cure. A truly unique event that combines the community's philanthropic spirit with Coloradans' love for the great outdoors - all in an effort to combat the most frequently diagnosed cancer worldwide. Upwards of 1,500 enthusiastic participants strap on their snowshoes in an effort to stomp out breast cancer, a disease that impacts 1 in every 7 women in Colorado.


Dec
16
2016

From enhanced variant calling to immune repertoire analysis: Greater assay design and analytics with Archer software updates

In this webinar, Brent Lutz, Product Manager of Software, and Doug Wendel, Senior Director of Software, will detail new Assay Designer and Analysis features designed to leverage and maximize the unique power of the patented Anchored Multiplex PCR (AMP™) target enrichment chemistry used in Archer NGS assays. Their talk will cover: • Enhanced variant calling via error correction and multi-sample noise reduction • Immune repertoire analysis • Archer Quiver™ Fusion Database customization • REST API for robust workflow integration • Mix & match cached targets for simple and fast custom assays • Integration with third party reporting providers


Nov
14
2016

Anchored Multiplex PCR patent is issued to inventors at Massachusetts General Hospital

ArcherDX, the leader in next-generation sequencing (NGS)-based gene fusion detection products, announced today the issuance of the first patent for Anchored Multiplex PCR (AMP™), the technology that forms the foundation of the company’s products.


Aug
17
2016

Archer announces Research Challenge Grant Winners

Archer awards 5 recipients up to 192 free reactions (24 kits with 8 reactions each) of an Archer Assay of their choosing and training from our expert Field Applications Specialists.


Jul
19
2016

Characterizing hematologic malignancies with ArcherDX blood cancer assays

This webinar will review multiple applications ArcherDX® FusionPlex® and VariantPlex™ blood cancer assays to address the significant clinical implications in the diagnosis and management of hematologic malignancies.


Aug
28
2015

Evolution of NGS-based detection of fusions, SNVs and CNVs using Anchored Multiplex PCR

Brian Kudlow, PhD, discusses the challenges of cancer genomics and how Archer technology addresses those challenges in the laboratory. Dr. Kudlow also discuss what Archer technology is moving towards in the future.

Subscribe to stay in the loop







How to contact us

Address

2477 55th Street, Suite 202

Boulder, CO 80301

Phone

Phone: (877) 771 1093

Phone: (303) 357 9001

All content © 2018 ArcherDX, Inc.

For Research Use Only. Not for use in diagnostic procedures. For Research Use Only. Not for use in diagnostic procedures.